WO2023199091 - HETEROCYCLIC COMPOUND
National phase entry:
Publication Number
WO/2023/199091
Publication Date
19.10.2023
International Application No.
PCT/IB2022/053399
International Filing Date
12.04.2022
Title **
[English]
HETEROCYCLIC COMPOUND
[French]
COMPOSÉ HÉTÉROCYCLIQUE
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
IKEDA, Shuhei
PAWLICZEK, Martin Alexander
KIMURA, Eiji
HATTORI, Yasushi
PIRA, Marilena
MIGUELEZ-RAMOS, Javier
TOKUNAGA, Norihito
MIYANOHANA, Yuhei
HOASHI, Yasutaka
KAJITA, Yuichi
ITO, Yoshiteru
KOIKE, Tatsuki
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4510 | |
| EPO | Filing, Examination, Granting | 27701 | |
| Japan | Filing, Examination, Granting | 2977 | |
| South Korea | Filing, Examination, Granting | 3730 | |
| USA | Filing, Examination, Granting | 17340 |
Total:
56,258
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I) is useful as an agent for the prophylaxis or treatment of narcolepsy.[French]
Le problème décrit par la présente invention est de fournir un composé hétérocyclique ayant une activité agoniste sur le récepteur de l'orexine de type 2. A cet effet, l'invention concerne un composé représenté par la formule (I), qui est utile en tant qu'agent pour la prophylaxie ou le traitement de la narcolepsie.